1.05
+0.035(+3.45%)
Currency In USD
| Previous Close | 1.01 |
| Open | 1.01 |
| Day High | 1.14 |
| Day Low | 0.99 |
| 52-Week High | 1.55 |
| 52-Week Low | 0.82 |
| Volume | 281,132 |
| Average Volume | 409,269 |
| Market Cap | 3.45M |
| PE | -0.35 |
| EPS | -2.99 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 1.1 |
| Change | 0.04 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $15.05 as of May 31, 2025 at a share price of $1.05. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 4 years ago, it would be worth $58.33 as of May 31, 2025 at a share price of $1.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 13, 2025 12:00 PM GMT
Several Key Clinical Readouts in Addition to New Study Initiations Expected in 2025SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-si
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
GlobeNewswire Inc.
Apr 28, 2025 12:45 PM GMT
ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarterSOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical compa
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
GlobeNewswire Inc.
Mar 31, 2025 12:30 PM GMT
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and